213 related articles for article (PubMed ID: 12880975)
21. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
[TBL] [Abstract][Full Text] [Related]
22. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
[TBL] [Abstract][Full Text] [Related]
23. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
24. Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an
Orienti I; Farruggia G; Nguyen F; Guan P; Calonghi N; Kolla V; Chorny M; Brodeur GM
Int J Nanomedicine; 2020; 15():6873-6886. PubMed ID: 32982239
[TBL] [Abstract][Full Text] [Related]
25. Liposome-mediated therapy of neuroblastoma.
Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
[TBL] [Abstract][Full Text] [Related]
26. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Maurer BJ; Kang MH; Villablanca JG; Janeba J; Groshen S; Matthay KK; Sondel PM; Maris JM; Jackson HA; Goodarzian F; Shimada H; Czarnecki S; Hasenauer B; Reynolds CP; Marachelian A
Pediatr Blood Cancer; 2013 Nov; 60(11):1801-8. PubMed ID: 23813912
[TBL] [Abstract][Full Text] [Related]
28. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract][Full Text] [Related]
29. p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma.
Ganeshan VR; Schor NF
Cancer Chemother Pharmacol; 2014 Feb; 73(2):271-9. PubMed ID: 24253178
[TBL] [Abstract][Full Text] [Related]
30. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
31. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
[TBL] [Abstract][Full Text] [Related]
33. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
35. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
36. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
37. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Orienti I; Zuccari G; Bergamante V; Carosio R; Gotti R; Cilli M; Montaldo PG
Biomacromolecules; 2007 Oct; 8(10):3258-62. PubMed ID: 17883277
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
Ohta S; Igarashi S; Honda A; Sato S; Hanai N
Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
[TBL] [Abstract][Full Text] [Related]
39. The Pyrazolo[3,4-
Rango E; Pastorino F; Brignole C; Mancini A; Poggialini F; Di Maria S; Zamperini C; Iovenitti G; Fallacara AL; Sabetta S; Clementi L; Valoti M; Schenone S; Angelucci A; Ponzoni M; Dreassi E; Botta M
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327462
[TBL] [Abstract][Full Text] [Related]
40. A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.
Orienti I; Nguyen F; Guan P; Kolla V; Calonghi N; Farruggia G; Chorny M; Brodeur GM
Drug Des Devel Ther; 2019; 13():4305-4319. PubMed ID: 31908416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]